-
Mashup Score: 8
Zachary Klaassen interviews Laurence Albiges about the CaboPoint Phase II Trial. Dr. Albiges discusses the evolving landscape of second-line treatment for clear cell renal cell carcinoma (RCC) after first-line immunotherapy combinations. The CaboPoint study evaluates cabozantinib as a pure second-line treatment in patients who have failed either nivolumab-ipilimumab or an IO-TKI strategy….
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 8
Zachary Klaassen interviews Laurence Albiges about the CaboPoint Phase II Trial. Dr. Albiges discusses the evolving landscape of second-line treatment for clear cell renal cell carcinoma (RCC) after first-line immunotherapy combinations. The CaboPoint study evaluates cabozantinib as a pure second-line treatment in patients who have failed either nivolumab-ipilimumab or an IO-TKI strategy….
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#CaboPoint trial: Cabozantinib in second-line #RCC treatment. @AlbigesL @GustaveRoussy joins @zklaassen_md @GACancerCenter discussing the evolving landscape of 2nd-line treatment for clear cell RCC after first-line immunotherapy combinations > https://t.co/kFQ70tU5NS https://t.co/O4PBGfVjPc
-
-
Mashup Score: 9
Zachary Klaassen interviews Laurence Albiges about the CaboPoint Phase II Trial. Dr. Albiges discusses the evolving landscape of second-line treatment for clear cell renal cell carcinoma (RCC) after first-line immunotherapy combinations. The CaboPoint study evaluates cabozantinib as a pure second-line treatment in patients who have failed either nivolumab-ipilimumab or an IO-TKI strategy….
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#CaboPoint trial: Cabozantinib in second-line #RCC treatment. @AlbigesL @GustaveRoussy joins @zklaassen_md @GACancerCenter discussing the evolving landscape of 2nd-line treatment for clear cell RCC after first-line immunotherapy combinations > https://t.co/kFQ70tU5NS https://t.co/O4PBGfVjPc
-
-
Mashup Score: 9
Zachary Klaassen interviews Laurence Albiges about the CaboPoint Phase II Trial. Dr. Albiges discusses the evolving landscape of second-line treatment for clear cell renal cell carcinoma (RCC) after first-line immunotherapy combinations. The CaboPoint study evaluates cabozantinib as a pure second-line treatment in patients who have failed either nivolumab-ipilimumab or an IO-TKI strategy….
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
#CaboPoint trial: Cabozantinib in second-line #RCC treatment. @AlbigesL @GustaveRoussy joins @zklaassen_md @GACancerCenter discussing the evolving landscape of 2nd-line treatment for clear cell RCC after first-line immunotherapy combinations > https://t.co/kFQ70tU5NS https://t.co/O4PBGfVjPc
-
#CaboPoint trial: Cabozantinib in second-line #RCC treatment. @AlbigesL @GustaveRoussy joins @zklaassen_md @GACancerCenter discussing the evolving landscape of 2nd-line treatment for clear cell RCC after first-line immunotherapy combinations > https://t.co/kFQ70tU5NS https://t.co/O4PBGfVjPc